{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T13:44:00Z","timestamp":1769348640681,"version":"3.49.0"},"reference-count":17,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,10,29]]},"abstract":"<jats:p>The mortality rate for Stevens-Johnson syndrome (SJS) is estimated to be \u223c12% and for toxic epidermal necrolysis (TEN) it is around 30%. It continues to be a severe life-threatening drug reaction. We present a 60-year-old Caucasian man with a medical history significant for breast cancer status post mastectomy and chemotherapy with docetaxel and cyclophosphamide who presented with severe mucositis and a progressing skin rash consistent with SJS. He was started on high-dose corticosteroids and IVIG but continued to have worsening mucosal ulcerations and severe bleeding from the oral, conjunctival and genital mucosa. He underwent several rounds of plasmapheresis and additional high-dose steroids with mild improvement in the mucocutaneous manifestations. He subsequently developed respiratory failure, which required mechanical ventilation, as well as disseminated intravascular coagulation, diffuse alveolar haemorrhage, with <jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia which led to his demise on hospital day 15.<\/jats:p>","DOI":"10.1136\/bcr-2016-217255","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T08:36:02Z","timestamp":1479285362000},"page":"bcr2016217255","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Case of Steven-Johnson Syndrome in a male with breast cancer secondary to docetaxel\/cyclophosphamide therapy"],"prefix":"10.1136","volume":"2016","author":[{"given":"Benjamin","family":"Jarrett","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Arizona, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehem","family":"Ghazala","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Arizona, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care, University of Arizona, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60789-2"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61112-X"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention.","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2332\/allergolint.55.27","article-title":"Immune mechanisms in drug allergy","volume":"55","author":"Roujeau","year":"2006","journal-title":"Allergol Int"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.5","doi-asserted-by":"crossref","unstructured":"Sawada Y . Docetaxel-induced Steven-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes. JEADV, 2009:1327\u201349.","DOI":"10.1111\/j.1468-3083.2009.03183.x"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1365-2133.1996.tb03915.x","article-title":"Steven-Johnson syndrome induced by cyclophosphamide\u2014a report of two cases","volume":"135","author":"Assier-Bonnet","year":"1996","journal-title":"Br J Dermatol"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.7","unstructured":"Valeyrie-Allanore L , Roujeau JC . Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis). In: Goldsmith LA , Katz SI , Gilchrest BA , et al , eds. Fitzpatrick's dermatology in general medicine. 8th edn. New York: McGraw-Hill, 2012."},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.8","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690170041005"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.9","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(91)90751-P"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.10","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.3.323"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.13","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304909"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional IV immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"42","author":"Aihara","year":"2015","journal-title":"J Dermatol"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.15","doi-asserted-by":"publisher","DOI":"10.1159\/000070957"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.08.039"},{"key":"2025082700002906000_2016.nov15_1.bcr2016217255.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00192.x"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-217255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:00:39Z","timestamp":1756278039000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-217255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":17,"alternative-id":["10.1136\/bcr-2016-217255"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-217255","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]}}}